Previous 10 | Next 10 |
BERWYN, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing treatments for neurodegenerative diseases announced today that the United States Patent and Trademark Office (USPTO) has granted the Company a patent with c...
ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST PR Newswire Company to hold R&D webcast today at 4:00 pm ET to review ongoing...
ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST PR Newswire Phase 2/3 AD Study continues to make stea...
ANNOVIS BIO TO HOLD LIVE WEBCAST TO REVIEW ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE CLINICAL PROGRAMS PR Newswire Webcast to be held on Thursday, April 20 th at 4pm EDT . BERWYN, Pa. , April 13, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE:...
2023-04-12 13:13:16 ET Summary Investor confusion surrounding Annovis’s interim analysis of its Phase 3 Parkinson's (PD) study highlights the need, in my view, for improved PR processes at Annovis. The company will have ~9 months to improve communications leading up to the ...
2023-04-11 09:35:18 ET Clinical-stage drug platform company addressing neurodegenerative diseases, Annovis Bio ( NYSE: ANVS ) has raised ~$8.7M. As previously disclosed, on March 31, 2023, the company entered into an ATM equity offering. On April 4, 2023, the comp...
ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION PR Newswire BERWYN, Pa. , April 11, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenera...
2023-04-04 08:30:22 ET Clearmind Medicine ( CMND ) -51% . Nogin ( NOGN ) -45% . ZIM Integrated Shipping Services ( ZIM ) -24% . AMC Entertainment Holdings ( AMC ) -24% rises on filed settlement of stock conversion lawsuit. Chicken Soup f...
2023-04-03 13:28:55 ET Gainers: Guardforce AI ( GFAI ) +126% . Nogin ( NOGN ) +110% . Harbor Custom Development ( HCDI ) +33% . Indonesia Energy Corporation ( INDO ) +30% . Pulse Biosciences ( PLSE ) +29% . Barnwell Industrie...
2023-04-03 10:02:08 ET Gainers: Heska ( HSKA ) +20% . Heron Therapeutics ( HRTX ) +19% . InterCure ( INCR ) +17% . Innate Pharma ( IPHA ) +15% . Apellis Pharmaceuticals ( APLS ) +14% . Losers: OncoSec Medical ( ONCS...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...